Collaboration between Sygnis AG and ECACC for licensing and distribution of Caco-2 cell line
Sygnis AG enters into a collaboration agreement with ECACC to significantly expand Sygnis' Caco-2 business. Under the collaboration, ECACC will organize that companies obtain the license for the use of the Caco-2 cell line from Sygnis in the US and afterwards will provide the Caco-2 materials directly.
Partnership between BioNTech and Genentech to develop individualized mRNA cancer therapies
BioNTech has agreed to collaborate with Roche’s Genentech to develop and commercialize mRNA based, individualized cancer vaccines. The agreement will see the companies jointly develop indi...
